Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 35, 2014, Pages 12823-12828

  Crane, Courtney A ^a,b   Austgen, Kathryn ^a,d   Haberthur, Kristen ^b   Hofmann, Carly ^a   Moyes, Kara White ^b   Avanesyan, Lia ^c   Fong, Lawrence ^a   Campbell, Michael J ^a   Cooper, Stewart ^c   Oakes, Scott A ^a   Parsa, Andrew T ^a   Lanier, Lewis L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Cancer; Glioma; LDH5; Tumor evasion

Indexed keywords

CANCER; GLIOMA; LDH5; TUMOR EVASION;

BRAIN NEOPLASMS; CELL LINE, TUMOR; GLIOBLASTOMA; GLIOMA; GPI-LINKED PROTEINS; HEK293 CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOENZYMES; KILLER CELLS, NATURAL; L-LACTATE DEHYDROGENASE; MONOCYTES; MYELOID CELLS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K;

EID: 84907227971     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1413933111     Document Type: Article

References (30)

1. Stupp R, et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996.
2. Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267-296.
3. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5(4):263-274.
4. Iannello A, Raulet DH (2014) Immunosurveillance of senescent cancer cells by natural killer cells. Oncolmmunology 3(1):e27616.
5. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H (2013) Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 31:413-441.
6. Orr MT, Lanier LL (2010) Natural killer cell education and tolerance. Cell 142(6):847-856.
7. Champsaur M, Lanier LL (2010) Effect of NKG2D ligand expression on host immune responses. Immunol Rev 235(1):267-285.
8. Guerra N, et al. (2008) NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28(4):571-580.
9. Crane CA, et al. (2010) TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro-oncol 12(1):7-13.
10. Diaz-Montero CM, Finke J, Montero AJ (2014) Myeloid-derived suppressor cells in cancer: Therapeutic, predictive, and prognostic implications. Semin Oncol 41(2):174-184.
11. Nausch N, Galani IE, Schlecker E, Cerwenka A (2008) Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells. Blood 112(10):4080-4089.
12. Groh V, Wu J, Yee C, Spies T (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419(6908):734-738.
13. Giatromanolaki A, et al.; Tumour and Angiogenesis Research Group (2006) Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis. Gynecol Oncol 103(3):912-918.
14. Kolev Y, Uetake H, Takagi Y, Sugihara K (2008) Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: Association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis. Ann Surg Oncol 15(8):2336-2344.
15. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL; Tumour Angiogenesis Research Group (2006) Lactate dehydrogenase 5 expression in operable colorectal cancer: Strong association with survival and activated vascular endothelial growth factor pathway-a report of the Tumour Angiogenesis Research Group. J Clin Oncol 24(26):4301-4308.
16. Koukourakis MI, Kontomanolis E, Giatromanolaki A, Sivridis E, Liberis V (2009) Serum and tissue LDH levels in patients with breast/gynaecological cancer and benign diseases. Gynecol Obstet Invest 67(3):162-168.
17. Copur S, et al. (1989) Lactate dehydrogenase and its isoenzymes in serum from patients with multiple myeloma. Clin Chem 35(9):1968-1970.
18. Dasgupta S, Bhattacharya-Chatterjee M, O' Malley BW, Jr, Chatterjee SK (2005) Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer. J Immunol 175(8):5541-5550.
19. Eisele G, et al. (2006) TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain 129(Pt 9):2416-2425.
20. McSharry BP, et al. (2008) Adenovirus E3/19K promotes evasion of NK cell recognition by intracellular sequestration of the NKG2D ligands major histocompatibility complex class I chain-related proteins A and B. J Virol 82(9):4585-4594.
21. Campbell JA, Trossman DS, Yokoyama WM, Carayannopoulos LN (2007) Zoonotic orthopoxviruses encode a high-affinity antagonist of NKG2D. J Exp Med 204(6):1311-1317.
22. Mincheva-Nilsson L, Baranov V (2014) Cancer exosomes and NKG2D receptor-ligand interactions: Impairing NKG2D-mediated cytotoxicity and anti-tumour immune surveillance. Semin Cancer Biol, 10.1016/j.semcancer.2014.02. 010.
23. Castriconi R, et al. (2003) Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 100(7):4120-4125.
24. Koukourakis MI, et al. (2009) Lactate dehydrogenase 5 expression in squamous cell head and neck cancer relates to prognosis following radical or postoperative radiotherapy. Oncology 77(5):285-292.
25. Husain Z, Huang Y, Seth P, Sukhatme VP (2013) Tumor-derived lactate modifies antitumor immune response: Effect on myeloid-derived suppressor cells and NK cells. J Immunol 191(3):1486-1495.
26. Champsaur M, et al. (2010) Intact NKG2D-independent function of NK cells chronically stimulated with the NKG2D ligand Rae-1. J Immunol 185(1):157-165.
27. Oppenheim DE, et al. (2005) Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 6(9):928-937.
28. Coudert JD, Scarpellino L, Gros F, Vivier E, Held W (2008) Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways. Blood 111(7):3571-3578.
29. Coudert JD, et al. (2005) Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 106(5):1711-1717.
30. Ogasawara K, et al. (2003) Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity 18(1):41-51.